跳至主要内容
临床试验/JPRN-UMIN000016736
JPRN-UMIN000016736已完成未知

Daily versus intermittent inhaled fluticasone in toddlers with recurrent wheezing - DIFTO study

Jikei University0 个研究点目标入组 500 人开始时间: 2015年5月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
12months-old 至 59months-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1)Patients in whom switching to fluticasone is difficult before enrollment (2)Patients in whom discontinuing such drugs will be difficult; LABA, theophylline, DSCG, LTRA, suplatast (3)Patients who has been treated for asthma with systemic steroids (oral or injection) for over 3 months within 1 year before enrollment (4)Patients who has been treated for asthma with systemic steroids (oral or injection) within 2 weeks before enrollment (5)Patients who cannot inhale fluticasone properly (6)Patients who are/will be treated with growth hormone (7)Patients in whom the body weight at birth was less than 2,000g (8)Patients in whom asthma severity was mild intermittent at enrollment (9)Patients who has been treated with antibiotics for sinusitis (10)Patients in whom evaluation of wheezing is difficult because of such complications; severe allergic rhinitis, congenital respiratory diseases, congenital neurological diseases, congenital heart diseases (11)Patients who suffers from GERD (12)Patients who are hypersensitive to steroids (13)Patients who has been enrolled in another clinical trial (14)Patients who was evaluated to be inappropriate for enrollment

研究者

相似试验

已完成
4 期
Comparative efficacy of daily inhaled fluticasone propionate and episodic inhaled combined salmeterol/fluticasone propionate in children with recurrent wheezingrecurrent wheezingEfficacy&#44Daily&#44Episodic&#44Inhaled corticosteroids&#44Recurrent wheezing
TCTR20180614002Queen Sirikit National Institute of Child Health72
进行中(未招募)
不适用
A 6-month study to assess the safety and benefit of inhaled fluticasone propionate/salmeterol combination compared with inhaled fluticasone propionate in the treatment of adolescents (12 years and over) and adults with asthma.AsthmaMedDRA version: 17.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2011-001644-29-CZGlaxoSmithKline Research & Development Limited11,664
已完成
4 期
Daily versus as-needed use of fluticasone furoate nasal spray in patients with allergic rhinitis: A randomized controlled trialmoderate&#45severe persistent allergic rhinitisallergic rhinitis&#44perennial&#44fluticasone furoate&#44intranasal corticosteroid&#44as&#45needed&#44regular&#44treatment
TCTR20170310002Siriraj research development fund, Faculty of medicine Siriraj hospital, Mahidol university110
进行中(未招募)
不适用
The Pharmacokinetics of Inhaled Fluticasone Propionate delivered as Monodisperse Aerosols - Pharmacokinetics of inhaled monodisperse Fluticasone PropionateHealthy volunteers and mild to moderate asthmaMedDRA version: 9.1Level: LLTClassification code 10052996Term: Inhalation therapyMedDRA version: 9.1Level: LLTClassification code 10053349Term: Pharmacokinetic studyMedDRA version: 9.1Level: PTClassification code 10003553Term: Asthma
EUCTR2008-002139-34-GBImperial College London30
进行中(未招募)
不适用
A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthmaChronic disease of the lungs characterized by airway inflammation,bonchoconstriction and increased airway responsiveness.MedDRA version: 16.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2011-003338-15-DEGlaxoSmithKline Research and Development Limited575